Geneticure Information

Geneticure develops genetic tests that help clinicians choose the right hypertension therapy before treatment starts. Uncontrolled high blood pressure is among the most common and costly problems in medicine. Most patients cycle through several medications before reaching control, and interventional options such as renal denervation work well for some patients and poorly for others. Geneticure’s tests analyze a patient’s genetic profile through proprietary algorithms grounded in cardiovascular physiology to identify which therapy is most likely to work for that individual. The platform addresses two clinical decisions. Medication guidance matches patients to the antihypertensive drug classes most likely to lower their blood pressure. Renal denervation response prediction identifies which patients are most likely to benefit from the procedure; the method has been evaluated in a blinded validation study and is protected by U.S. Patent No. 12,351,873. Geneticure works with medical device companies, health systems and clinical research partners to bring genetically guided treatment selection into practice. Founded in 2014, the company operates in Minnesota and Arizona, with a scientific team drawn from Mayo Clinic, the University of Minnesota and the University of Arizona.